Search results
Results From The WOW.Com Content Network
(Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug ...
By David Carnevali (Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two ...
oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel 7126 7885 8 trastuzumab: breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 ...
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R , ABL , c-KIT , FLT3 , and PDGFR-β .
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
BERLIN (Reuters) -Novartis said on Thursday it has launched a tender offer to acquire MorphoSys, a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion). Reuters ...
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...